Collaboration and Other Agreements - Collaboration and License Agreement with Janssen Biotech, Inc (Details Narrative) (Collaboration and License Agreement with Janssen Biotech, Inc (Janssen), USD $) In Thousands, unless otherwise specified	1 Months Ended	12 Months Ended
	Dec. 31, 2011	Jun. 30, 2012
Non-refundable upfront payment upon execution	$ 150,000
Maximum milestone payments received	825,000
Percent Of Cost Sharing Arrangement Janssen Share	60.00%
Percent Of Cost Sharing Arrangement By Company	40.00%
Description of sharing cost and pre tax lossess (the "Excess Amounts")		In the event that our share of aggregate development costs in any given calendar year, together with any other amounts that become due from us, plus our share of pre-tax loss (if any) for any calendar quarter in such calendar year, less our share of pre-tax profit (if any) for any calendar quarter in such calendar year, exceeds $50,000,000, then amounts that are in excess of $50,000,000 (the Excess Amounts) shall be borne by Janssen.
Maximum cost sharing amount incurred		50,000
Description of interest rate calculation		Interest shall be accrued on the outstanding balance with interest calculated at the average annual European Interbank Offered Rate (EURIBOR) for the EURO or London Interbank Offered Rate (LIBOR) for U.S. Dollars as reported in the Wall Street Journal, plus 2%, calculated on the number of days from the date on which our payment would be due to Janssen.
Interest rate on outstanding balance		2.00%
Maximum total excess amounts plus interest	225,000
Maximum percentage of interest on oustanding excess amount (in percent)	5.00%
Maximum interest on oustanding excess amount	25,000
Interest expense recognized in connection with the Excess Amounts		0
Description of net profit sharing arrangement for the commercialization		Agreement also includes a 50/50 net profit sharing arrangement for the commercialization of any products resulting from the collaboration.
Estimated weighted average cost of capital (in percent)	12.00%
Minimum license royalty rates (in percent)	30.00%
Maximum license royalty rates (in percent)	40.00%
Research And Development Costs Total Under Janssen Collaboration Agreement		43,272
Portion of research and development expense of Janssen		18,381
Decrease in general and administrative expense		4
Accounts receivable due from Janssen		5,799
Continued Development Progress
Maximum milestone payments received	250,000
Achievement of Regulatory Progress
Maximum milestone payments received	225,000
Regulatory Approval
Maximum milestone payments received	350,000
Licenses
Non-refundable upfront payment upon execution	70,605
Committee Services
Non-refundable upfront payment upon execution	14,982
Services revenue recognized period	17 years
Development Services
Non-refundable upfront payment upon execution	$ 64,413
Services revenue recognized period	9 years